Artiva Biotherapeutics (ARTV) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Artiva Biotherapeutics

NasdaqGM•Healthcare•Biotechnology

$10.86+0.07(0.01%)Market open

Market Cap

$339.35M

P/B

1.0x

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.

How this company scores

WeakMetricSide Score: 32/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Growth (3/25).

Profitability8/25

Growth3/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Long cash runwayInterest easily coveredNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 284.8x5y range 146.7x – 290.9x

P/B · 1.0x5y range 0.2x – 1.5x

Currently near its 8-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $339.35M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-93.46M
TTM Op. Income: $-96.15M
Q. Op. Income: $-26.89M
TTM Net Income: $-90.82M
Q. Net Income: $-25.00M
EPS: $-0.63
Shares Out.: $39.41M

$0 in TTM revenue declined 100.0% YoY, reaching $0 last quarter. TTM EBITDA of $-93.46M and TTM operating income of $-96.15M show growth is flowing through to the bottom line. However, net income is negative at $90.82M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is down 100% — a steady trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -2689000000.0%
Net Margin: -2500500000.0%

Op. margin of -2689000000.0% is down 408000000.0% YoY — costs are rising relative to revenue. Net margin at -2500500000.0% Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: 1.0x

P/S of 0.0x and P/B of 1.0x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $368.63M
Cash: $301.45M
Long-Term Debt: N/A
Book Value: $347.50M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-20.36M
TTM Free Cash Flow: $-76.91M
FCF Margin: N/A
FCF / Net Income: 0.8

TTM FCF of $-76.91M on $-20.36M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 9% — an improving trend.